O que há de novo na terapêutica médica da diabetes mellitus tipo 2?
A diabetes mellitus tipo 2 é uma doença progressiva com uma prevalência crescente. O antidiabético ideal será aquele que permita um bom controlo glicémico e altere a história natural da doença, com consequente diminuição da morbilidade e mortalidade associadas às complicações da doença. Terá ainda q...
Saved in:
| Main Authors: | M. J. Matos, P. Freitas, D. Carvalho |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidade Católica Portuguesa, Instituto de Ciências da Saúde
2011-12-01
|
| Series: | Cadernos de Saúde |
| Subjects: | |
| Online Access: | https://revistas.ucp.pt/index.php/cadernosdesaude/article/view/3043 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use
by: D. V. Kurkin, et al.
Published: (2023-05-01) -
The impact of innovative glucose-lowering drugs on the course and outcome of COVID-19 in patients with type 2 diabetes mellitus
by: T. N. Markova, et al.
Published: (2024-05-01) -
Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study
by: Makoto Ohara, et al.
Published: (2025-04-01) -
Systematic Review of Cardiovascular Outcomes with Sulfonylureas, GLP-1 RA, and DPP-4 Inhibitors in Type 2 Diabetes Mellitus
by: Koo Thai Hau, et al.
Published: (2024-07-01) -
The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
by: Juris J. Meier
Published: (2019-12-01)